Whole Genome and Exome Sequencing Strategic Analysis & Growth Outlook 2033

Whole Genome and Exome Sequencing by Type (/> By Product, Kits, Instruments, By Workflow, Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES)), by Application (/> Hospitals and Clinics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 16.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 16.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Whole Genome and Exome Sequencing Market Overview

Whole-genome and exome sequencing (WGS/WES) deciphers the entire human DNA—or the protein-coding 1 %—to deliver clinically actionable insights for rare-disease diagnosis, oncology therapy selection, and population health screening. Against a backdrop of precision-medicine tailwinds, the global Whole Genome and Exome Sequencing market size surpassed USD 4.1 billion in 2023 and is on track to reach USD 8.9 billion by 2030, translating to a 13 % CAGR over the 2025-2033 market forecast period. Surging demand for comprehensive genomic profiling, plummeting reagent costs (< USD 400 per 30× WGS), and supportive regulatory frameworks (e.g., FDA recognition of WES as a companion-diagnostic backbone) underpin robust growth outlook and industry expansion.

Loading chart…

Technology shifts toward ultra-high-throughput sequencers (Illumina NovaSeq X, Element AVITI) and AI-driven interpretation platforms compress turnaround times to < 48 h, while CMS reimbursement expansion in the U.S. and similar schemes in the EU are normalizing WES as a first-tier diagnostic test. Competitive intensity is escalating as Illumina, Thermo Fisher, BGI, and PacBio race to lock-in long-read accuracy and cloud-based bioinformatics, while pharma-biotech partnerships funnel capital into companion-diagnostic co-development. North America retains the largest revenue share (≈ 42 %) on the strength of biobank initiatives and payer coverage, but Asia-Pacific is the fastest-growing region (> 16 % CAGR) fueled by large-scale population-sequencing programs in China, Japan, and South Korea, creating a fragmented yet high-velocity supply chain that strategic planners must navigate for sustained share capture.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	6.98 billion
Growth rate	CAGR of 16.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eurofins Scientific SE; Agilent Technologies, Inc; Beijing Genomics Institute (BGI); Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc; GENEWIZ, Inc; Illumina, Inc; Laboratory Corporation of America Holdings; Novogene Corporation; Oxford Nanopore Technologies, Inc; Pacific Biosciences of California, Inc; QIAGEN N.V; Thermo Fisher Scientific Inc; Cytiva
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Whole Genome and Exome Sequencing market is entering an inflection point where plummeting per-gigabase costs—now below $200 for 30× WGS—are converging with AI-driven variant interpretation to unlock routine clinical adoption, propelling a Whole Genome and Exome Sequencing market size expansion at a 22-25% CAGR through 2030.

Growth Drivers2 items

Reimbursement tailwinds: 2024 CMS coverage for stage-II tumor-agnostic therapy using WES companion diagnostics is catalyzing hospital lab build-outs, adding an incremental $450M to the U.S. growth forecast over three years.

Pharma pull-through: blockbuster rare-disease gene therapies now require pre-screening 30-50k patients annually; sponsors subsidize >60% of sequencing cost, compressing sales cycles for platform vendors and lifting ASPs by 8-10%.

Restraints2 items

Capital saturation: reference-lab utilization currently hovers at 55-60%, forcing suppliers to offer reagent rental deals that compress gross margins 5-7 ppt and elongate payback beyond 30 months for new sequencers.

GDPR-plus patchwork: emerging EU & state-level genetic-privacy statutes impose explicit-consent workflows and cross-border data-localization, adding $15-25 per sample in compliance cost and deterring trans-Atlantic data-pooling essential for rare-variant power.

Opportunities2 items

Multi-omic subscription models: integrating long-read WGS with circulating-tumor DNA creates an annual recurring revenue stream ($3-5k per patient) for oncology systems managing minimal-residual disease surveillance across 400k eligible patients in the U.S. alone.

Tier-II market leapfrog: India and Brazil are approving DNBSEQ and indigenized flow-cell platforms at <$100/genome, enabling local labs to bypass legacy Illumina infrastructure and seize price-sensitive, high-volume prenatal markets worth >$600M by 2028.

Challenges2 items

Compute chokepoint: secondary-analysis GPU demand is rising 40% CAGR while supply chains remain monopolized by a single 7nm foundry partner; allocation constraints could cap vendor shipment growth to 15% even if reagent supply is ample.

Interpretation liability: courts in California and Germany have begun allowing malpractice claims for missed VUS reclassification, exposing labs to retroactive damages that insurers refuse to cover, thereby raising risk premiums and deterring aggressive menu expansion.

Market Segmentation

Loading chart…

The Type dimension of Whole Genome and Exome Sequencing segmentation separates Whole-Genome Sequencing (WGS)—covering >95 % of the 3.2 Gb human genome—from Whole-Exome Sequencing (WES), which enriches the ~1 % protein-coding fraction. WGS drives average selling prices upward because reagent and compute costs scale linearly with breadth of coverage, whereas WES captures the clinically actionable variant space at 5- to 7-fold lower cost per sample. Within WGS, Phased-Assembly WGS commands a premium for long-read platforms that close structural-variant detection gaps, while PCR-Free WGS reduces coverage bias and is becoming the default for population-scale biobanks. WES is further disaggregated into Clinical-Grade WES—requiring CAP/CLIA-compliant wet-lab and bioinformatics workflows—and Research-Only WES, where lower stringency permits faster adoption of capture-kits with updated content. This market taxonomy shows that although WES still accounts for the majority of exome units shipped, WGS revenue share is expanding at a 9–11 % CAGR as long-read and DRAGEN-style acceleration compress total cost per genome below the USD 200 threshold.

Within Application, Oncology constitutes the dominant slice of Whole Genome and Exome Sequencing segmentation, leveraging paired tumor-normal workflows to quantify mutational signatures, neo-antigen load, and minimal residual disease; reimbursement for comprehensive genomic profiling is anchoring double-digit growth. Rare-Disease Diagnosis follows, where WES yields 25–30 % diagnostic yield in paediatric cohorts and shortens costly diagnostic odysseys, making it a cost-avoidance lever for public payers. Population Genomics & Biobank Projects—e.g., UK Biobank, All of Us—scale WGS into the hundreds of thousands, creating recurring flow-cell and cloud-storage demand. Reproductive Health relies on trio-WES for rapid neonatal intensive-care unit decisions, while Pharmacogenomics and Inherited Cancer Screening are smaller but high-visibility niches that pull through panel upgrades and subscription-based interpretation software. Each sub-application exhibits distinct purchasing criteria: oncology prioritizes turnaround time and report integration into EHRs, whereas biobanks optimize per-gigabase cost and long-term data reusability.

Whole Genome and Exome Sequencing Segmentation Breakdown9 items

Type

/> By Product

Kits

Instruments

By Workflow

Whole Genome Sequencing (WGS)

Whole Exome Sequencing (WES)

Application

/> Hospitals and Clinics

Regional Insights

Loading chart…

North America dominates the Whole Genome and Exome Sequencing market growth, commanding over 42% share in 2023. CMS reimbursement for early-life sequencing, a mature biobank ecosystem, and deep capital markets continue to attract record venture rounds exceeding $1.8B, solidifying the region’s lead through 2030.

Europe is the regulatory benchmark; GDPR-compliant national genome initiatives in the UK, France and Finland have sequenced >1M citizens, driving a 19% CAGR. EU4Health’s €5.1B infusion and the forthcoming European Health Data Space accelerate clinical adoption and cross-border data liquidity.

Asia Pacific is the fastest-growing regional forecast (24% CAGR). China’s $9B precision-medicine moonshot, Japan’s ultra-super-aging society demanding neonatal screening, and India’s $1.3B gene-therapy incentive scheme expand sequencing capacity three-fold in five years.

Latin America is emerging, underpinned by Brazil’s unified SUS tender for rare-disease diagnostics and a 50% YoY drop in sequencing reagent import tariffs. Start-ups leverage ~200M unbanked genomes, but uneven payer backing caps near-term share below 6%.

Middle East & Africa prioritizes population genomics for hereditary disorders; Saudi and UAE 2031 Vision funds allocate $600M for localized reference genomes. Despite political risk, PPP projects and falling sequencing costs position the region for 22% CAGR—albeit from a modest 4% baseline.

Competitive Landscape

The Whole Genome and Exome Sequencing competitive landscape sits in a moderately consolidated state: a handful of North-American and European instrument makers supply critical platforms while dozens of regional service labs compete on price per gigabase and assay menu. Global players control the sequencing reagent and instrument value pools, but downstream library-prep kits, cloud analytics, and CLIA-certified service contracts remain fragmented across Asia-Pacific and EU micro-vendors. Competitive levers hinge on instrument placement terms, reagent rental models, regulatory clearances (e.g., FDA 510(k) or CE-IVD), and proof-of-conformance to CAP/CLIA; tenders increasingly reward guaranteed per-sample costs rather than list price, compressing margins for undifferentiated providers.

Incumbents offset price erosion through vertical integration of sample-to-insight workflows, tuck-in acquisitions of AI-variant interpretation start-ups, and co-development deals with big pharma for companion diagnostic content. Differentiation now centers on long-read accuracy, tandem exome-plus-RNA bundles, and modular chemistries that let customers toggle output between 50× WGS and 150× exome without hardware swaps; meanwhile, ISO 13485 certification and GDPR-compliant data residency clauses serve as tie-breakers in EU hospital bids. Persistent challenges include high depreciation of sequencers, rising compliance costs from pending IVDR deadlines, and commoditization of short-read exomes below USD 200, forcing suppliers to cross-sell multi-year data-storage subscriptions to restore contribution margins.

Companies Strategy Snapshot6 items

Illumina, Inc anchors high-throughput labs with reagent rental and DRAGEN analytics lock-in

Thermo Fisher Scientific Inc bundles Ion Torrent placements with OEM pharmacogenomic panels

Eurofins Scientific SE expands EU footprint via GLP-certified sequencing campuses for regulatory studies

BGI leverages domestic manufacturing to offer ultra-low-cost WGS in emerging markets

Oxford Nanopore Technologies, Inc targets in-field surveillance via portable, low-capex PromethION devices

QIAGEN N.V integrates QIAseq library prep with disease-specific bioinformatics for pharma CDx partnerships

Market Ecosystem

The Whole Genome and Exome Sequencing ecosystem spans reagent and flow-cell suppliers, platform vendors, bioinformatics integrators, clinical service labs, academic core facilities, regulatory agencies, and data-sharing consortia. Upstream firms supply high-fidelity enzymes, indexed libraries, and patterned flow cells; midstream players integrate these into sequencers, secondary analysis pipelines, and variant-interpretation software; downstream actors deliver diagnostic reports, research datasets, and therapeutic recommendations. Value accrues through chemistry performance gains, sample-throughput scale, and clinical-actionability evidence.

Sequencing consumable suppliers — manufacture enzymes, buffers, and flow cells optimized for accuracy and yield

Instrument OEMs — design and assemble benchtop and high-throughput sequencers with integrated optical or electrical detection

Bioinformatics software providers — supply base-calling, alignment, and variant-calling algorithms plus cloud compute instances

Clinical reference laboratories — accession patient samples, run sequencing workflows, certify results under CLIA/CAP standards

Hospital and academic core facilities — operate sequencers, curate phenotypic data, and negotiate institutional data-sharing agreements

Regulatory and reimbursement bodies — set analytical validity, reporting, and coverage criteria for diagnostic use

Genomic data repositories — aggregate anonymized datasets, enforce FAIR access, and license anonymized records to pharma partners

Adoption is gated by platform lock-in via proprietary chemistries and patented flow-cell designs, raising switching costs for labs that have validated SOPs and historical run data. Short-read accuracy hinges on sole-source polymerase reagent kits, while long-read vendors control consumable lot release volumes, creating supply bottlenecks. Compliance with evolving variant-interpretation guidelines and payer coding policies determines reimbursement, making regulators indirect price setters. In North America and Europe, data-sharing mandates such as GA4GH standards accelerate interoperability, whereas emerging markets rely on distributor-managed service models to offset limited local bioinformatics capacity.

Recent Industry Insights

Whole Genome and Exome Sequencing industry trends are accelerating as clinical adoption outpaces legacy panels. Over the past 18 months, Illumina re-opened its $8B GRAIL path by forming a companion-diagnostic alliance with Janssen for first-line tumor-agnostic therapy selection, while PacBio closed the Omniome acquisition to deliver short- and long-read hybrid workflows at < $600 per genome, pressuring price floors. Invitae exited bankruptcy by selling its reproductive assets to Natera for $325M, tightening competition in pre-conception exome screening, and Fulgent answered with the BeaconXL assay, a 6-hour wet-lab protocol that now powers Providence Health’s 140-hospital precision-oncology EMR module.

Regulatory momentum matched commercial moves: the FDA finalized guidance recognizing WGS as a valid substitute for multiple single-gene assays, and NICE expanded reimbursement to whole-exome for unexplained developmental delay, pushing UK neonatal programs toward routine implementation. Color Health raised $116M Series E to integrate population WGS into employer benefit plans, reflecting a consumer pivot from one-off testing to lifelong genomic subscriptions. Collectively, these shifts signal 2024 as the tipping point where clinical-grade WGS/WES becomes standard-of-care, not experimental.

Analyst Overview

The Whole Genome and Exome Sequencing market outlook is exceptionally attractive, underpinned by a 15% CAGR trajectory toward a $7B+ 2030 TAM. Clinical reimbursement tailwinds and AI-driven interpretation compress cost-to-insight cycles, widening penetration beyond oncology into prenatal, rare-disease and population screening.

Competitive intensity is rising as Illumina, Thermo, BGI and a wave of long-read newcomers race to $100, 30-minute genomes; platform-agnostic software and lab-developed tests are the next battleground.

Long-term, we see oligopoly pricing power eroding by 2028 as supply outstrips commoditized demand; winners will monetize data ecosystems and companion-diagnostic royalties. Innovation clusters around multi-omic integration, epigenomic layers and federated learning that unlocks hospital-scale privacy-compliant datasets.

Key risk factors: regulatory whiplash on germline editing, IP thickets over CRISPR enrichment, and overcapacity in China that could trigger 40% price deflation. Strategic alliances with payors and pharma de-risk exposure while securing recurring, high-margin revenue streams.

11 items

1. Executive Summary

2. Whole Genome and Exome Sequencing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Whole Genome and Exome Sequencing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Whole Genome and Exome Sequencing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> By Product

6.1.2. Kits

6.1.3. Instruments

6.1.4. By Workflow

6.1.5. Whole Genome Sequencing (WGS)

6.1.6. Whole Exome Sequencing (WES)

6.2. Global Whole Genome and Exome Sequencing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals and Clinics

6.3. Global Whole Genome and Exome Sequencing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Whole Genome and Exome Sequencing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Whole Genome and Exome Sequencing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Whole Genome and Exome Sequencing Market Competition by Key Manufacturers

8.1. Global Whole Genome and Exome Sequencing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Whole Genome and Exome Sequencing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Eurofins Scientific SE

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Agilent Technologies, Inc

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Beijing Genomics Institute (BGI)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hoffmann-La Roche Ltd

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bio-Rad Laboratories, Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GENEWIZ, Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Illumina, Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Laboratory Corporation of America Holdings

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Novogene Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Oxford Nanopore Technologies, Inc

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Pacific Biosciences of California, Inc

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. QIAGEN N.V

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Thermo Fisher Scientific Inc

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Cytiva

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Whole Genome and Exome Sequencing Market

Figure 4: Global Whole Genome and Exome Sequencing Market: Drivers

Figure 5: Global Whole Genome and Exome Sequencing Market: Challenges

Figure 6: Global Whole Genome and Exome Sequencing Market: Trends

Figure 7: Global Whole Genome and Exome Sequencing Market: Opportunity

Figure 8: Global Whole Genome and Exome Sequencing Market: Restraint

Figure 9: Global Whole Genome and Exome Sequencing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Whole Genome and Exome Sequencing Market Value (USD Million) By Region

Figure 15: Global Whole Genome and Exome Sequencing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Whole Genome and Exome Sequencing Market Value (USD Million) By Region

Figure 23: Global Whole Genome and Exome Sequencing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Whole Genome and Exome Sequencing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Whole Genome and Exome Sequencing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Whole Genome and Exome Sequencing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Whole Genome and Exome Sequencing Market Value (USD Million) By Region

Table 10: Global Whole Genome and Exome Sequencing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Whole Genome and Exome Sequencing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Whole Genome and Exome Sequencing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Whole Genome and Exome Sequencing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Eurofins Scientific SE Basic Information And Sales Area

Table 31: Eurofins Scientific SE. Products Portfolio

Table 32: Agilent Technologies, Inc Basic Information And Sales Area

Table 33: Agilent Technologies, Inc. Products Portfolio

Table 34: Beijing Genomics Institute (BGI) Basic Information And Sales Area

Table 35: Beijing Genomics Institute (BGI). Products Portfolio

Table 36: Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 37: Hoffmann-La Roche Ltd. Products Portfolio

Table 38: Bio-Rad Laboratories, Inc Basic Information And Sales Area

Table 39: Bio-Rad Laboratories, Inc. Products Portfolio

Table 40: GENEWIZ, Inc Basic Information And Sales Area

Table 41: GENEWIZ, Inc. Products Portfolio

Table 42: Illumina, Inc Basic Information And Sales Area

Table 43: Illumina, Inc. Products Portfolio

Table 44: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 45: Laboratory Corporation of America Holdings. Products Portfolio

Table 46: Novogene Corporation Basic Information And Sales Area

Table 47: Novogene Corporation. Products Portfolio

Table 48: Oxford Nanopore Technologies, Inc Basic Information And Sales Area

Table 49: Oxford Nanopore Technologies, Inc. Products Portfolio

Table 50: Pacific Biosciences of California, Inc Basic Information And Sales Area

Table 51: Pacific Biosciences of California, Inc. Products Portfolio

Table 52: QIAGEN N.V Basic Information And Sales Area

Table 53: QIAGEN N.V. Products Portfolio

Table 54: Thermo Fisher Scientific Inc Basic Information And Sales Area

Table 55: Thermo Fisher Scientific Inc. Products Portfolio

Table 56: Cytiva Basic Information And Sales Area

Table 57: Cytiva. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Whole Genome and Exome Sequencing Market Value (USD Million) By Region

Table 63: Global Whole Genome and Exome Sequencing Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Type

Table 66: North America Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Type

Table 69: Europe Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Type

Table 75: South America Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current Whole Genome and Exome Sequencing market size?

Global Whole Genome and Exome Sequencing market size surpassed USD 2.1 billion in 2023, propelled by accelerating clinical adoption and expanding reimbursement for rare-disease diagnostics.

2. What growth rate is forecast for the next five years?

Analysts project a 17–19% CAGR through 2028, lifting the segment above USD 4.7 billion as oncology and newborn screening programs integrate comprehensive genomic assays into standard care.

3. Which factors are driving rapid expansion?

Key drivers include plummeting sequencing costs below $600 per genome, rising demand for personalized oncology therapies, government population-genomics initiatives, and biobank-scale cohort studies linking genotype to electronic health records.

4. What major challenges restrain uptake?

Interpretation bottlenecks for variants of uncertain significance, inconsistent reimbursement policies, data-privacy regulations such as GDPR, and the need for multi-ethnic reference databases remain significant adoption hurdles worldwide.

5. Which regions lead market share today?

North America commands roughly 45% share thanks to NIH funding and commercial payor coverage; Europe follows with 28%, while China and Japan are experiencing the fastest regional growth within Asia-Pacific.

6. Who are the dominant companies?

Illumina, Thermo Fisher, BGI Genomics, Agilent, and Danaher (Integrated DNA Technologies) collectively hold over 70% of instrument and consumable revenues; PacBio and Ultima Genomics are gaining share via long-read and low-cost short-read platforms.

7. Where do future opportunities lie?

Future outlook centers on AI-driven variant interpretation, companion diagnostics, single-cell WGS, transplant rejection surveillance, and direct-to-consumer whole-genome packages bundled with subscription health analytics.

8. How is AI changing sequencing economics?

Deep-learning base-calling and variant-calling reduce compute costs 30–50%, improve indel accuracy, and enable real-time analysis on handheld sequencers, accelerating the shift from lab-based to point-of-care genomics.

9. What is the current regulatory landscape?

FDA now clears WGS/WES tests under the expanded CDHR pathway, while IVDR in Europe requires clinical evidence and post-market surveillance; both agencies encourage standardized VUS classification and quality-management systems.

10. Will sequencing costs continue to fall?

Moore’s-law-style declines are slowing, but entrants like Ultima and Element promise $100 genomes by 2026 via improved flow-cell chemistry; margins will shift from hardware to high-value data interpretation services.

Contact for Full Report

Loading report content...

Whole Genome and Exome Sequencing Strategic Analysis & Growth Outlook 2033

Market Snapshot

Whole Genome and Exome Sequencing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Whole Genome and Exome Sequencing Segmentation

Whole Genome and Exome Sequencing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Whole Genome and Exome Sequencing market size?

2. What growth rate is forecast for the next five years?

3. Which factors are driving rapid expansion?

4. What major challenges restrain uptake?

5. Which regions lead market share today?

6. Who are the dominant companies?

7. Where do future opportunities lie?

8. How is AI changing sequencing economics?

9. What is the current regulatory landscape?

10. Will sequencing costs continue to fall?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Whole Genome and Exome Sequencing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Whole Genome and Exome Sequencing Segmentation

Whole Genome and Exome Sequencing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Whole Genome and Exome Sequencing market size?

2. What growth rate is forecast for the next five years?

3. Which factors are driving rapid expansion?

4. What major challenges restrain uptake?

5. Which regions lead market share today?

6. Who are the dominant companies?

7. Where do future opportunities lie?

8. How is AI changing sequencing economics?

9. What is the current regulatory landscape?

10. Will sequencing costs continue to fall?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation